• 1. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 2. Enantiomeric two-fold interpenetrated 3D zinc(ii) coordination networks as a catalytic platform: significant difference between water within the cage and trace water in transesterification?
  Eunkyung Choi,Minjoo Ryu,Haeri Lee,Ok-Sang Jung Dalton Trans., 2017,46, 4595-4601
• 3. Enabling stable MnO2 matrix for aqueous zinc-ion battery cathodes?
  Yiding Jiao,Liqun Kang,Jasper Berry-Gair,Kit McColl,Jianwei Li,Haobo Dong,Hao Jiang,Ryan Wang,Furio Corà,Dan J. L. Brett,Ivan P. Parkin J. Mater. Chem. A, 2020,8, 22075-22082
• 4. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 5. Exciting clusters, what does off-resonance actually mean??
  Goonay Yousefalizadeh,Shideh Ahmadi,Nicholas J. Mosey,Kevin G. Stamplecoskie Nanoscale, 2021,13, 242-252

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridines and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives

Introduction to 2-(propan-2-yl)-3-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (CAS No. 2096337-14-1)

2-(propan-2-yl)-3-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine, with the CAS number 2096337-14-1, is a versatile organic compound that has garnered significant attention in the fields of chemical synthesis and medicinal chemistry. This compound is a member of the boronic ester family and is characterized by its unique structural features, which include a pyridine ring and a tetramethyl dioxaborolane moiety. These structural elements endow the compound with a range of valuable properties, making it a valuable reagent in various synthetic transformations and biological applications.

The synthesis of 2-(propan-2-yl)-3-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine typically involves the coupling of a boronic acid or ester with a halopyridine derivative. The use of palladium-catalyzed cross-coupling reactions, such as the Suzuki-Miyaura coupling, has been particularly effective in this context. The tetramethyl dioxaborolane group serves as a protected boronic acid equivalent, which can be readily converted to the corresponding boronic acid under mild conditions. This feature makes the compound highly useful in sequential synthetic strategies where intermediate protection and deprotection steps are required.

In the realm of medicinal chemistry, 2-(propan-2-yl)-3-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine has shown promise as a building block for the development of novel therapeutic agents. The pyridine ring is a common pharmacophore in many bioactive molecules, and its presence in this compound can facilitate interactions with biological targets such as enzymes and receptors. Recent studies have explored the use of boronic esters in drug discovery, particularly in the design of inhibitors for specific protein-protein interactions (PPIs). The ability to fine-tune the electronic and steric properties of the boronic ester through functional group modifications makes it an attractive scaffold for lead optimization.

The stability and reactivity of 2-(propan-2-yl)-3-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine have been extensively studied. The tetramethyl dioxaborolane group provides enhanced stability compared to free boronic acids, which can be prone to hydrolysis under certain conditions. This increased stability is crucial for maintaining the integrity of the compound during storage and handling. Additionally, the presence of the tert-butyl group on the pyridine ring can influence the lipophilicity and solubility properties of the molecule, which are important considerations in drug design.

In terms of biological activity, preliminary studies have indicated that 2-(propan-2-yl)-3-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine exhibits promising anti-inflammatory and anti-cancer properties. For instance, it has been shown to inhibit certain kinases involved in inflammatory signaling pathways, suggesting potential applications in treating inflammatory diseases such as rheumatoid arthritis. Furthermore, its ability to modulate protein-protein interactions has led to investigations into its use as a targeted therapy for cancer treatment.

The environmental impact and safety profile of 2-(propan-2-yl)-3-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine have also been evaluated. While boronic esters are generally considered to be relatively safe compared to other organometallic compounds, it is important to handle them with appropriate precautions to avoid exposure and environmental contamination. Studies have shown that this compound does not exhibit significant toxicity at relevant concentrations and can be safely used in laboratory settings when proper safety protocols are followed.

In conclusion, 2-(propan-2-yl)-3-(tetramethyl-1,3,2-dioxaborolan-2-y l)pyridine (CAS No. 2096337-14-1) is a multifaceted compound with a wide range of applications in chemical synthesis and medicinal chemistry. Its unique structural features make it an invaluable reagent for synthetic transformations and a promising scaffold for the development of novel therapeutic agents. Ongoing research continues to uncover new possibilities for its use in various scientific and industrial contexts.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)